Topline data from Phase 3 study in patients with Tourette syndrome shows statistical significance between ecopipam and placebo for both the primary efficacy endpoint in pediatric subjects (p = 0.0084) and secondary efficacy endpoint in pediatric and adult subjects (p=0.0050) CHICAGO—February 25, 2025—Emalex Biosciences announced … Read more
Annual Awards Program Recognizes Innovation in the Global Life Sciences and Biotechnology Industries CHICAGO, November 19, 2024 – Emalex Biosciences was named “Neuroscience Therapeutics Company of the Year” in the fourth annual BioTech Breakthrough Awards program conducted by BioTech Breakthrough, a leading independent market intelligence … Read more
– Long-term safety data collected in pediatric patients treated with investigational drug ecopipam; durable treatment effect reported with no evidence of tachyphylaxis – CHICAGO, October 5, 2023 – An open-label extension study of 121 pediatric patients with Tourette syndrome evaluated the safety profile of the … Read more
– Enrolled patients will receive medication for up to 24 weeks; 90 sites planned for North America and Europe – CHICAGO, March 1, 2023 – Emalex Biosciences announced that the first patient was dosed in its Phase 3 clinical trial evaluating ecopipam for the treatment of … Read more
– Study data shows investigational new drug, ecopipam, reduced total number of tics by 30% compared to placebo – CHICAGO—January 11, 2023 – A Phase 2b clinical trial involving more than 150 children and adolescents with Tourette syndrome found ecopipam significantly reduced the total number of … Read more